Alembic Pharmaceuticals' Q2 FY 2026-27 Quarterly Results

Result Summary

• Alembic Pharmaceuticals Ltd reported a 21.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 36.6%.
• Its expenses for the quarter were up by 12.1% QoQ and 28.6% YoY.
• The net profit increased 93.7% QoQ and increased 81.8% YoY.
• The earnings per share (EPS) of Alembic Pharmaceuticals Ltd stood at 17.05 during Q2 FY 2026-27.

Financial Statments for Q2 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Alembic Pharmaceuticals Ltd is a prominent entity in the pharmaceutical industry, primarily engaged in manufacturing and marketing a wide range of pharmaceutical products. These products include active pharmaceutical ingredients (APIs), generic formulations, and branded formulations across various therapeutic segments. The company operates within the highly competitive pharmaceutical sector, which is characterized by rigorous regulatory standards, significant research and development investments, and a focus on innovation. While specific recent developments for Alembic Pharmaceuticals Ltd are not provided, the company is known for its continuous efforts in expanding its product portfolio and enhancing its manufacturing capabilities.

Revenue

For the second quarter of fiscal year 2027, Alembic Pharmaceuticals Ltd reported a total income of ₹2618.59 crores, marking a significant increase of 21.0% compared to the previous quarter and a notable year-over-year growth of 36.6% from Q2FY26. This substantial rise in revenue suggests a robust demand for the company's products or a successful expansion into new markets. The increase in total income indicates effective sales strategies or product launches that have contributed to the company's financial performance.

Profitability

During Q2FY27, Alembic Pharmaceuticals Ltd achieved a profit before tax (PBT) of ₹439.32 crores, reflecting an impressive quarter-over-quarter growth of 98.4% and an equally substantial year-over-year increase of 97.6%. The company's profit after tax (PAT) stood at ₹333.91 crores, demonstrating a strong growth of 93.7% from the previous quarter and 81.8% on a year-over-year basis. The earnings per share (EPS) for this quarter was ₹17.05, showing a similar growth trajectory as PAT, with a 93.7% increase from Q1FY27 and an 81.4% increase from Q2FY26. These figures underline the company's enhanced profitability during this period.

Operating Metrics

The total expenses for Alembic Pharmaceuticals Ltd in Q2FY27 were ₹2179.27 crores, which represents a 12.1% increase from the previous quarter and a 28.6% increase from Q2FY26. The tax expense for the quarter was ₹104.04 crores, exhibiting a significant quarter-over-quarter growth of 110.2% and a year-over-year increase of 160.0%. These operating metrics provide insight into the company's cost management and tax obligations, reflecting operational efficiencies or changes in the tax structure affecting the company.